Skip to main content
. Author manuscript; available in PMC: 2022 Sep 15.
Published in final edited form as: Neuropharmacology. 2021 Jul 8;196:108702. doi: 10.1016/j.neuropharm.2021.108702

Figure 1. Systemic administration of reboxetine, a noradrenaline reuptake inhibitor, blunts binge-like ethanol intake in C57BL6/J mice.

Figure 1.

10 mg/kg i.p. reboxetine blunted binge-like ethanol (A; n=21) intake and BECs (B; n=21). Following ethanol testing, these mice underwent sucrose testing wherein 10 mg/kg reboxetine blunted intake of a 3% sucrose solution (C; n=19). Alterations in intake patterns were not secondary to altered locomotor or anxiety-like states, as 10 mg/kg reboxetine pretreatment prior to OFT failed to alter total distance traveled (D; n=7) and center time (E; n=7) relative to vehicle-injected cohorts (n=7). Data collapsed across males and females due to absence of sex effects. (F) Further analyses of ethanol intake data indicated that reboxetine blunted intake in mice with High baseline ethanol intake (upper 50% of a median-split) and not in mice with Low baseline intake (lower 50% of a median-split). values represent mean ± SEM. * indicates p<0.05 in paired t-test.